E-Cigarette Nicotine Delivery Among Young Adults by Nicotine Form, Concentration, and Flavor: A Crossover Randomized Clinical Trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

To examine the effects of nicotine form and concentration and e-liquid flavor on subjective effects ratings, vaping behavior, and nicotine uptake among young adults who use e-cigarettes.

Why It Was Studied

Concerns have been raised about the abuse liability of modern e-cigarettes that use acidic additives to form nicotine salts, making the inhalation of nicotine smoother than freebase nicotine.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

In this single-blind, within-participant, crossover randomized clinical trial, a convenience sample of young adults aged 21 to 25 years who currently used e-cigarettes was recruited from December 2021 to August 2023, for in-person research laboratory visits in Columbus, Ohio.

Participants completed up to 9 vaping sessions, starting with their usual e-cigarette brand in the first session followed by 1 of 8 laboratory-prepared e-liquids in a randomly assigned order in each subsequent session.

How the Study Was Run

In design terms this was a randomized, single-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

In this single-blind Therapeutic nicotine (patch, non-peptide) study one party knew the assignments and the other did not.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

Each session included a 5-minute, 10-puff standardized vaping period followed by 30 minutes of ad libitum vaping.

What Was Measured

Topics PubMed links to this paper include Electronic Nicotine Delivery Systems, Nicotine, Vaping and Flavoring Agents.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (JAMA network open), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.